Scattering of Rubella IgG Titer in Cytomegalovirus IgG Sero-Positive Adult Women in Bangladesh

Abstract

Primary infections caused by rubella and Cytomegalovirus (CMV) can front-runner to thoughtful complications in pregnancy. Rubella and CMV screening of adult women is not consistently conceded out in Bangladesh. The aim of this study was to determine the prevalence of rubella infection among CMV IgG sero-positive adult women. Throughout this study we reviewed the testing records of CMV IgG sero-positive adult women aged of 17-36 years who presented by random at immunology laboratory records at Dhaka Hospital Ltd., Bangladesh. Between January, 2014 to July, 2014, 51 anti-CMV IgG positive adult women were included and retrospectively evaluated in this study. The mean age of the selected CMV IgG sero-positive adult women in this study was 24.67±5.46 years. The highest sero-positivity for the anti-CMV IgG (15, 41.2%) and anti-Rubella IgG (14, 37.25%) were documented in 22-26 age group and followed by 29.4% for CMV IgG and 27.45% for Rubella IgG in 17-21 age group. The mean CMV IgG titer was 289.49 IU mL-1 for 17-21 age group while 99.03 IU mL-1 in Rubella IgG titer, 248.65 IU mL-1 CMV IgG titer for 22-26 age group whereas 103.21 IU mL-1 Rubella IgG, 275.06 IU mL-1 CMV IgG titer and 116.36 IU mL-1 Rubella IgG titer for 27-31 age group and 301.60 IU mL-1 CMV IgG titer although 109.76 IU mL-1 Rubella IgG titer for 32-36 age group. The median of CMV IgG titer and Rubella IgG titer were 233.80 IU mL-1 and 68.20 IU mL-1 with 298.00 and 126.90 IU mL-1 of 75% percentile respectively. Although high prevalence of CMV IgG and Rubella IgG were found (41.2 and 37.25%) in 22-26 age group, but the highest mean CMV IgG titer (301.60 IU mL-1) found in 32-36 age group while highest mean Rubella IgG titer (116.36 IU mL-1) was found in 27-31 age group. So, Deterrent actions must be taken to lessening the mortality and morbidity related to congenital rubella and CMV infections in fetus. The rubella and CMV status should be investigated before pregnancy and sero-negative females can be recommended for vaccination.